Week 52 outcomes of 180 lupus nephritis pts (IV, VI, III) from AMP academic centers (rx w/ standard of care) showed 22% complete resp,  22% partial resp, 42% non-responder& 14% undetermined. 8/180 (4.4%) had CR sustained Wk 12 to 52; 10% PR. An unmet need! https://t.co/UfYDKqHq1D https://t.co/zUIgvsZY6m

Cochrane Review: How Good is Ultrasound Diagnosing GCA? Is temporal artery ultrasound (US) equivalent or superior to the reference standard of temporal artery biopsy (TAB) when diagnosing giant cell arteritis (GCA)? https://t.co/BWzP3K8dCo https://t.co/DMu19sPMQv

Orismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor studied in phase 2b RCT in 202 moderate-to-severe psoriasis pts vs PBO. At wk 16, Orismilast was better at PASI 75 (40%-49% vs PBO 16.5%; P <.05) and PASI90 (22%-28% vs 8%; P <.05) https://t.co/wSmiO2Hr5W https://t.co/gMiQUfT6EG

Mayo study of 1643 #RA pts (Dzduration 7 yrs) found 4 clusters based on # of comorbidities (Cluster 1 [42%] few comorbidities & cluster 4 [7%] > 10). Cluster 1 w/ good prog/survival; but cluster 4 was older, less DMARDs/biologics https://t.co/NTJvuBujdp https://t.co/wZycwYDfFS

Vasculitis Pearls Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks https://t.co/RnaHa54F2T https://t.co/aRpAdz1o8y

How do you manage enthesitis? Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). https://t.co/9SHM5aZAly https://t.co/KWYnhymsVr

IV zoledronic acid (ZA) of PBO was given to 222 pts with symptomatic knee osteoarthritis (without severe joint space narrowing) and after 7 yrs of F/U, ZA had no effect on Knee OA progression w/ similar TKR Rates (39% vs 30%) https://t.co/P09EvRmApO https://t.co/s5fL1unM45

Retrospective analysis of the Australian Scleroderma Cohort Study, finds 43% of SSc pts have evidence of myopathy. From 1786 participants, 155 had prox. weakness, 24% CK elevation & 4% prox weak+CK^ (latter in more severe SSc) https://t.co/cB4Ul6VMB2 https://t.co/uAIMaotPdv

Long-Term, open-label study enrolled EGPA (MIRRA study) required prednisolone ≥5 mg/d, pts cont mepolizumab 300 mg Sc q 4 wks +SOC. 100 pts - 71% completed, 3% d/C due to AEs. Exposure~38 mos; 38% serious AEs (30/100PYs) (worsening of asthma, EGPA https://t.co/8qrbFigc9T https://t.co/7QP8qGfsSm

Top 5 Clinical Pearls in RA Management #RNL2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in RA." https://t.co/QrtnbeLxRZ https://t.co/5K2YRzvzcp

Serious infx (SIE) is prevalent in SLE given RTX. TOtal of 174 SLE pts on RTX -- SIE rate was high at 51/100 PYs (Pneumonia 30/100 PYs; PJP in 6.1/100 PYs).12 deaths. SIE risk factors were CKD (HR 2.9), Pred ≥15 /day (HR 3.5). HCQ decreased SIE (HR 0.35) https://t.co/8GcSQx8nxh https://t.co/oZvMgTxKVI

APIPPRA Trial: Abatacept in at-risk rheumatoid arthritis patients Abatacept has been studied in seropositive clinically suspect arthralgia patients (at risk for rheumatoid arthritis) and shows the potential to delay or prevent the disease. https://t.co/w944yaXNOd https://t.co/UvTVRTK1er